OS from randomization for patients with FLT3^mutat AML diagnosis by MRD status at baseline (after chemotherapy) and randomized treatment arm. MRD was determined at study entry by multiparameter flow cytometry using a different-from-normal method with a 0.1% positivity threshold. FLT3^mut includes both FLT3-ITD and FLT3-TKD mutations.